Home » Stocks » IMV

IMV Inc. (IMV)

Stock Price: $3.66 USD 0.12 (3.39%)
Updated Jan 27, 2021 1:31 PM EST - Market open
Market Cap 235.90M
Revenue (ttm) 433,588
Net Income (ttm) -20.89M
Shares Out 49.65M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $3.66
Previous Close $3.54
Change ($) 0.12
Change (%) 3.39%
Day's Open 3.46
Day's Range 3.37 - 3.69
Day's Volume 231,264
52-Week Range 1.40 - 5.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 4 weeks ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vac...

Newsfile Corp - 1 month ago

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and ph...

Business Wire - 1 month ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies ...

Business Wire - 1 month ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines a...

Business Wire - 2 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...

Seeking Alpha - 2 months ago

IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript

Business Wire - 2 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update

Business Wire - 2 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...

Business Wire - 2 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Comp...

Business Wire - 2 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...

Business Wire - 2 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers

Business Wire - 3 months ago

HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine cand...

Business Wire - 3 months ago

HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Investigators enrolled and dosed the first cluster of participants in Appili's Phase 2 CONTROL clinical trial evaluating fa...

Business Wire - 3 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Re-establishes At-the-Market Facility

Zacks Investment Research - 3 months ago

IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Business Wire - 3 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...

Business Wire - 3 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...

Seeking Alpha - 3 months ago

Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine.

Business Wire - 4 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against inf...

Seeking Alpha - 5 months ago

IMV Inc. (IMV) CEO Frederic Ors on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 5 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Second Quarter 2020 Financial Results

Zacks Investment Research - 5 months ago

IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 5 months ago

IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 5 months ago

IMV (NASDAQ: IMV) shares are trading higher on Wednesday after the company announced it has received CA$4.75 million ($3.59 million) in funding from the Canadian government agencies for a COVI...

Business Wire - 5 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against in...

Business Wire - 5 months ago

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).

Zacks Investment Research - 6 months ago

IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

The Motley Fool - 6 months ago

Good news for Moderna was bad news for several of its rivals.

Other stocks mentioned: ALT, BNTX, INO, SRNE
24/7 Wall Street - 6 months ago

IMV Inc. (NASDAQ: IMV) shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.

Benzinga - 6 months ago

Imv Inc (NASDAQ: IMV) share are ripping higher on above-average volume following an update by the company on its coronavirus vaccine program.

Seeking Alpha - 8 months ago

IMV Inc. (IMV) CEO Frederic Ors on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 9 months ago

IMV, Inc. (IMV) CEO Frederic Ors on Q4 2019 Results - Earnings Call Transcript

Benzinga - 9 months ago

Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.

Other stocks mentioned: ALT, JNJ
Zacks Investment Research - 10 months ago

IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.

Benzinga - 10 months ago

Micro-cap Canadian biopharma Imv Inc (NASDAQ: IMV) said Wednesday that it is advancing the clinical development of a DPX-based vaccine candidate for the coronavirus, joining a number of biotec...

Zacks Investment Research - 10 months ago

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

IMV, Inc. (IMV) CEO Frederic Ors on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

IMV INC (IMV) delivered earnings and revenue surprises of -33.33% and 175.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

IMV, Inc. (IMV) CEO Frederic Ors on Q2 2019 Results - Earnings Call Transcript

About IMV

IMV operates as a clinical-stage biopharmaceutical company. It is developing cancer immunotherapies and vaccines against infectious diseases, including COVID-19. The company's delivery platform (DPX) programs immune cells directly within the human body to produce robust, specific, and sustained target killing capabilities. Its lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple Phase 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphom... [Read more...]

Industry
Biotechnology
Founded
2000
CEO
Frederic Ors M.B.A., B.Sc., M.A.
Employees
62
Stock Exchange
NASDAQ
Ticker Symbol
IMV
Full Company Profile

Financial Performance

In 2019, IMV Inc.'s revenue was 568,000, an increase of 17.60% compared to the previous year's 483,000. Losses were -27.37 million, 24.8% more than in 2018.

Financial numbers in millions CAD.
Financial Statements